-
1
-
-
28844449677
-
Cyclin D1-negative mantle cell lymphoma: A clinicopathologic study based on gene expression profiling
-
Fu K, Weisenburger DD, Greiner TC, et al.: Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005, 106:4315-4321.
-
(2005)
Blood
, vol.106
, pp. 4315-4321
-
-
Fu, K.1
Weisenburger, D.D.2
Greiner, T.C.3
-
2
-
-
27244434794
-
Pathogenesis of mande-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways
-
Fernandez V, Hartmann E, Ott G, et al.: Pathogenesis of mande-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005, 23:6364-6369.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6364-6369
-
-
Fernandez, V.1
Hartmann, E.2
Ott, G.3
-
3
-
-
3242762286
-
Genomic DNA-chip hybridization in t(11, 14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions
-
Kohlhammer H, Schwaenen C, Wessendorf S, et al.: Genomic DNA-chip hybridization in t(11, 14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 2004, 104:795-801.
-
(2004)
Blood
, vol.104
, pp. 795-801
-
-
Kohlhammer, H.1
Schwaenen, C.2
Wessendorf, S.3
-
4
-
-
0013224058
-
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
-
Rosenwald A, Wright G, Wiestner A, et al.: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
-
(2003)
Cancer Cell
, vol.3
, pp. 185-197
-
-
Rosenwald, A.1
Wright, G.2
Wiestner, A.3
-
5
-
-
33645729415
-
The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma
-
Katzenberger T, Petzoldt C, Holler S, et al.: The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006, 107:3407.
-
(2006)
Blood
, vol.107
, pp. 3407
-
-
Katzenberger, T.1
Petzoldt, C.2
Holler, S.3
-
6
-
-
0035158697
-
Leukemic mantle cell lymphoma: Clinical and pathologic spectrum of twenty-three cases
-
Schlette E, Lai R, Onciu M, et al.: Leukemic mantle cell lymphoma: clinical and pathologic spectrum of twenty-three cases. Mod Pathol 2001, 14:1133-1140.
-
(2001)
Mod Pathol
, vol.14
, pp. 1133-1140
-
-
Schlette, E.1
Lai, R.2
Onciu, M.3
-
7
-
-
33644786965
-
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
-
Pott C, Schrader C, Gesk S, et al.: Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006, 107:2271-2278.
-
(2006)
Blood
, vol.107
, pp. 2271-2278
-
-
Pott, C.1
Schrader, C.2
Gesk, S.3
-
8
-
-
0141889260
-
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: Correlation with genomic aberrations, clinical characteristics, and outcome
-
Kienle D, Krober A, Katzenberger T, et al.: VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003, 102:3003-3009.
-
(2003)
Blood
, vol.102
, pp. 3003-3009
-
-
Kienle, D.1
Krober, A.2
Katzenberger, T.3
-
9
-
-
34548523417
-
A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma
-
Hoster E, Dreyling N, Unterhalt M, et al.: A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2006, 108:814.
-
(2006)
Blood
, vol.108
, pp. 814
-
-
Hoster, E.1
Dreyling, N.2
Unterhalt, M.3
-
10
-
-
0031788754
-
Management of mantle cell lymphoma
-
Armitage JO: Management of mantle cell lymphoma. Oncology (Williston Park) 1998, 12:49-55.
-
(1998)
Oncology (Williston Park)
, vol.12
, pp. 49-55
-
-
Armitage, J.O.1
-
11
-
-
0037301982
-
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
-
Romaguera JE, Medeiros LJ, Hagemeister FB, et al.: Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003, 97:586-591.
-
(2003)
Cancer
, vol.97
, pp. 586-591
-
-
Romaguera, J.E.1
Medeiros, L.J.2
Hagemeister, F.B.3
-
12
-
-
0036499084
-
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival
-
Howard OM, Gribben JG, Neuberg DS, et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288-1294.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1288-1294
-
-
Howard, O.M.1
Gribben, J.G.2
Neuberg, D.S.3
-
13
-
-
0032422078
-
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma
-
Khouri IF, Romaguera J, Kantarjian H, et al.: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803-3809.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3803-3809
-
-
Khouri, I.F.1
Romaguera, J.2
Kantarjian, H.3
-
14
-
-
27244452464
-
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
-
Romaguera JE, Fayad L, Rodriguez MA, et al.: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013-7023.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7013-7023
-
-
Romaguera, J.E.1
Fayad, L.2
Rodriguez, M.A.3
-
15
-
-
33645590231
-
Phase II study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: A Wisconsin Oncology Network Study [abstract]
-
Kahl BS, McGovern, Blank J, et al.: Phase II study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: A Wisconsin Oncology Network Study [abstract]. Blood 2004, 104:1388.
-
(2004)
Blood
, vol.104
, pp. 1388
-
-
Kahl, B.S.1
-
16
-
-
0031896096
-
Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas
-
Decaudin D, Bosq J, Tertian G, et al.: Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998, 16:579-583.
-
(1998)
J Clin Oncol
, vol.16
, pp. 579-583
-
-
Decaudin, D.1
Bosq, J.2
Tertian, G.3
-
17
-
-
0034845543
-
Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma
-
Cohen BJ, Moskowitz C, Straus D, et al.: Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001, 42:1015-1022.
-
(2001)
Leuk Lymphoma
, vol.42
, pp. 1015-1022
-
-
Cohen, B.J.1
Moskowitz, C.2
Straus, D.3
-
18
-
-
8744274334
-
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
-
Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064-3071.
-
(2004)
Blood
, vol.104
, pp. 3064-3071
-
-
Forstpointner, R.1
Dreyling, M.2
Repp, R.3
-
19
-
-
33845693025
-
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma
-
Ritchie DS, Seymour JF, Grigg AP, et al.: The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007, 86:101-105.
-
(2007)
Ann Hematol
, vol.86
, pp. 101-105
-
-
Ritchie, D.S.1
Seymour, J.F.2
Grigg, A.P.3
-
20
-
-
85014234123
-
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: A prospective study
-
Lefrere F, Delmer A, Suzan F, et al.: Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002, 16:587-593.
-
(2002)
Leukemia
, vol.16
, pp. 587-593
-
-
Lefrere, F.1
Delmer, A.2
Suzan, F.3
-
21
-
-
0642368565
-
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma
-
Khouri IF, Lee MS, Saliba RM, et al.: Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003, 21:4407-4412.
-
(2003)
J Clin Oncol
, vol.21
, pp. 4407-4412
-
-
Khouri, I.F.1
Lee, M.S.2
Saliba, R.M.3
-
22
-
-
20644469242
-
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
-
Rummel MJ, Al-Batran SE, Kim SZ, et al.: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:3383-3389.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3383-3389
-
-
Rummel, M.J.1
Al-Batran, S.E.2
Kim, S.Z.3
-
23
-
-
33748319711
-
Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions [abstract]
-
Zelenetz A, Noy A, Pandit-Taskar M, et al.: Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions [abstract]. J Clin Oncol Proc ASCO 2006, 24:7560
-
(2006)
J Clin Oncol Proc ASCO
, vol.24
, pp. 7560
-
-
Zelenetz, A.1
Noy, A.2
Pandit-Taskar, M.3
-
24
-
-
33748324856
-
Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patents with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499) [abstract]
-
Smith M, Chen H, Gordon L, Horning S: Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patents with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499) [abstract]. J Clin Oncol 2006, 24:7503.
-
(2006)
J Clin Oncol
, vol.24
, pp. 7503
-
-
Smith, M.1
Chen, H.2
Gordon, L.3
Horning, S.4
-
25
-
-
24344492734
-
A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract]
-
Oki Y, Pro B, Depassand E, et al.: A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract]. Blood 2004, 104:2632.
-
(2004)
Blood
, vol.104
, pp. 2632
-
-
Oki, Y.1
Pro, B.2
Depassand, E.3
-
26
-
-
0036566227
-
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
-
Gopal AK, Rajendran JG, Petersdorf SH, et al.: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002, 99:3158-3162.
-
(2002)
Blood
, vol.99
, pp. 3158-3162
-
-
Gopal, A.K.1
Rajendran, J.G.2
Petersdorf, S.H.3
-
27
-
-
34548525578
-
Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results [abstract]
-
Morschhauser F, Leonard JP, Fayad L, et al.: Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results [abstract]. J Clin Oncol 2007, 25:8032.
-
(2007)
J Clin Oncol
, vol.25
, pp. 8032
-
-
Morschhauser, F.1
Leonard, J.P.2
Fayad, L.3
-
28
-
-
34548540008
-
Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin's lymphoma (NHL) [abstract]
-
Advani A, Giné E, Gisselbrecht C, et al.: Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood 2005, 106:230.
-
(2005)
Blood
, vol.106
, pp. 230
-
-
Advani, A.1
Giné, E.2
Gisselbrecht, C.3
-
29
-
-
33748110441
-
A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma [abstract]
-
Advani R, Furman R, Rosenblatt J, et al.: A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma [abstract]. Blood 2005, 108:1504.
-
(2005)
Blood
, vol.108
, pp. 1504
-
-
Advani, R.1
Furman, R.2
Rosenblatt, J.3
-
30
-
-
33646390886
-
Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL) [abstract]
-
Younes Y, Vose J, Zelenetz A, et al.: Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL) [abstract]. Blood 2005, 106:489.
-
(2005)
Blood
, vol.106
, pp. 489
-
-
Younes, Y.1
Vose, J.2
Zelenetz, A.3
-
31
-
-
24744457075
-
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma
-
Neelapu SS, Kwak LW, Kobrin CB, et al.: Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 2005, 11:986-991.
-
(2005)
Nat Med
, vol.11
, pp. 986-991
-
-
Neelapu, S.S.1
Kwak, L.W.2
Kobrin, C.B.3
-
32
-
-
33644659256
-
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
-
Peggs KS, Quezada SA, Korman AJ, Allison JP: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006, 18:206-213.
-
(2006)
Curr Opin Immunol
, vol.18
, pp. 206-213
-
-
Peggs, K.S.1
Quezada, S.A.2
Korman, A.J.3
Allison, J.P.4
-
33
-
-
2342613652
-
The proteasome: A suitable antineoplastic target
-
Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4:349-360.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 349-360
-
-
Adams, J.1
-
34
-
-
34548526934
-
Report of a phase II study of proteasome inhibitor bortezomib in patients with relapsed or refractory indolent and aggressive B-cell lymphomas [abstract]
-
Goy A, East K, Mesina F, et al.: Report of a phase II study of proteasome inhibitor bortezomib in patients with relapsed or refractory indolent and aggressive B-cell lymphomas [abstract]. J Clin Oncol Proc ASCO 2003, 22:2291.
-
(2003)
J Clin Oncol Proc ASCO
, vol.22
, pp. 2291
-
-
Goy, A.1
East, K.2
Mesina, F.3
-
35
-
-
20044376092
-
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
-
O'Connor OA, Wright J, Moskowitz C, et al.: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684.
-
(2005)
J Clin Oncol
, vol.23
, pp. 676-684
-
-
O'Connor, O.A.1
Wright, J.2
Moskowitz, C.3
-
36
-
-
23644452770
-
Phase II clinical study of bortezomib (VELCADE®) in patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) [abstract]
-
Strauss S, Maharaj L, Jim Stec J, et al.: Phase II clinical study of bortezomib (VELCADE®) in patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) [abstract]. Blood 2004, 104:1386.
-
(2004)
Blood
, vol.104
, pp. 1386
-
-
Strauss, S.1
Maharaj, L.2
Jim Stec, J.3
-
37
-
-
16844367553
-
Phase II trial of bortezomib in mantle cell lymphoma [abstract]. Oral Session
-
Belch A, Kouroukis C, Crump M, et al.: Phase II trial of bortezomib in mantle cell lymphoma [abstract]. Oral Session. Blood 2004, 104:608.
-
(2004)
Blood
, vol.104
, pp. 608
-
-
Belch, A.1
Kouroukis, C.2
Crump, M.3
-
38
-
-
34548522609
-
Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study [abstract]
-
Goy A, Bernstein S, Kahl BS, et al.: Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): results of the PINNACLE study [abstract]. J Clin Oncol Proc ASCO 2006, 24:7512.
-
(2006)
J Clin Oncol Proc ASCO
, vol.24
, pp. 7512
-
-
Goy, A.1
Bernstein, S.2
Kahl, B.S.3
-
39
-
-
33750625445
-
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
-
Fisher RI, Bernstein S, Kahl BS, et al.: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867-4874.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4867-4874
-
-
Fisher, R.I.1
Bernstein, S.2
Kahl, B.S.3
-
40
-
-
33746428098
-
Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin's lymphoma cells [abstract]
-
Goy A, Remache Y, Barkoh, et al.: Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin's lymphoma cells [abstract]. Blood 2004, 104:389a.
-
(2004)
Blood
, vol.104
-
-
Goy, A.1
Remache, Y.2
Barkoh3
-
41
-
-
20044396543
-
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
-
Goy A, Younes A, McLaughlin P, et al.: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:667-675.
-
(2005)
J Clin Oncol
, vol.23
, pp. 667-675
-
-
Goy, A.1
Younes, A.2
McLaughlin, P.3
-
42
-
-
33746010219
-
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
-
Richardson PG, Briemberg H, Jagannath S, et al.: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113-3120.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3113-3120
-
-
Richardson, P.G.1
Briemberg, H.2
Jagannath, S.3
-
43
-
-
33746056833
-
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: A possible surrogate marker of response?
-
Gerecitano J, Goy A, Wright J, et al.: Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 2006, 134:391-398.
-
(2006)
Br J Haematol
, vol.134
, pp. 391-398
-
-
Gerecitano, J.1
Goy, A.2
Wright, J.3
-
44
-
-
34250900229
-
Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: Final results. Oral Session
-
De Vos S, Dakhil SR, McLaughlin P, et al.: Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: final results. Oral Session. Blood 2006; 108.
-
(2006)
Blood
, pp. 108
-
-
De Vos, S.1
Dakhil, S.R.2
McLaughlin, P.3
-
45
-
-
34548541174
-
Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL)
-
O'Connor O, Hamlin P, Moskowitz C, et al.: Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL). J Clin Oncol 2007, 25:8051.
-
(2007)
J Clin Oncol
, vol.25
, pp. 8051
-
-
O'Connor, O.1
Hamlin, P.2
Moskowitz, C.3
-
46
-
-
33847297956
-
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma
-
Weigert O, Pastore A, Rieken M, et al.: Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007, 21:524-528.
-
(2007)
Leukemia
, vol.21
, pp. 524-528
-
-
Weigert, O.1
Pastore, A.2
Rieken, M.3
-
47
-
-
34247517943
-
Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma
-
Drach J, Kaufmann H, Pichelmayer O, et al.: Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma. J Clin Oncol 2006, 24:17522.
-
(2006)
J Clin Oncol
, vol.24
, pp. 17522
-
-
Drach, J.1
Kaufmann, H.2
Pichelmayer, O.3
-
48
-
-
33745892167
-
Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): Phase I results [abstract]
-
Leonard J, Furman R, Feldman E, et al.: Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results [abstract]. Blood 2005, 104:491.
-
(2005)
Blood
, vol.104
, pp. 491
-
-
Leonard, J.1
Furman, R.2
Feldman, E.3
-
49
-
-
35348876311
-
Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: A randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) [abstract]
-
Mounier N, Ribrag V, Haioun C, et al.: Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: A randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) [abstract]. J Clin Oncol 2007, 25:8010.
-
(2007)
J Clin Oncol
, vol.25
, pp. 8010
-
-
Mounier, N.1
Ribrag, V.2
Haioun, C.3
-
50
-
-
34548537359
-
Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses
-
Stewart KA, O'Connor OA, Alsina M, et al.: Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses. J Clin Oncol 2007, 25:8003.
-
(2007)
J Clin Oncol
, vol.25
, pp. 8003
-
-
Stewart, K.A.1
O'Connor, O.A.2
Alsina, M.3
-
51
-
-
23944481410
-
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
-
Witzig TE, Geyer SM, Ghobrial I, et al.: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005, 23:5347-5356.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5347-5356
-
-
Witzig, T.E.1
Geyer, S.M.2
Ghobrial, I.3
-
52
-
-
33747846726
-
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
-
Rudelius M, Pittaluga S, Nishizuka S, et al.: Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006, 108:1668-1676.
-
(2006)
Blood
, vol.108
, pp. 1668-1676
-
-
Rudelius, M.1
Pittaluga, S.2
Nishizuka, S.3
-
53
-
-
33749002279
-
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
-
Yee KW, Zeng Z, Konopleva M, et al.: Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006, 12:5165-5173.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5165-5173
-
-
Yee, K.W.1
Zeng, Z.2
Konopleva, M.3
-
54
-
-
33645635326
-
A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies
-
Feldman E, Giles F, Roboz G, et al.: A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol 2005, 23:6631.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6631
-
-
Feldman, E.1
Giles, F.2
Roboz, G.3
-
55
-
-
4944229959
-
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
-
Kaufmann H, Raderer M, Wohrer S, et al.: Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004, 104:2269-2271.
-
(2004)
Blood
, vol.104
, pp. 2269-2271
-
-
Kaufmann, H.1
Raderer, M.2
Wohrer, S.3
-
56
-
-
34147181695
-
Early results from a phase II study of lenalidomide monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma
-
Witzig TE, Vose JM, Kaplan HP, et al.: Early results from a phase II study of lenalidomide monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma. Blood 2006, 108:2482.
-
(2006)
Blood
, vol.108
, pp. 2482
-
-
Witzig, T.E.1
Vose, J.M.2
Kaplan, H.P.3
-
57
-
-
34548539145
-
A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/ refractory mantle cell lymphoma (MCL) with early evidence of efficacy
-
Wang M, Fayad L, Hagemeister F, et al.: A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/ refractory mantle cell lymphoma (MCL) with early evidence of efficacy. J Clin Oncol 2007, 25:8030.
-
(2007)
J Clin Oncol
, vol.25
, pp. 8030
-
-
Wang, M.1
Fayad, L.2
Hagemeister, F.3
-
58
-
-
34548542892
-
A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma
-
Younes A, Fanale M, Pro B, et al.: A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Ontology 2007, 25:8000.
-
(2007)
J Clin Ontology
, vol.25
, pp. 8000
-
-
Younes, A.1
Fanale, M.2
Pro, B.3
-
59
-
-
33644836549
-
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
-
O'Connor OA, Heaney ML, Schwartz L, et al.: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24:166-173.
-
(2006)
J Clin Oncol
, vol.24
, pp. 166-173
-
-
O'Connor, O.A.1
Heaney, M.L.2
Schwartz, L.3
-
60
-
-
33644873930
-
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma
-
Heider U, Kaiser M, Sterz J, et al.: Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 2006, 76:42-50.
-
(2006)
Eur J Haematol
, vol.76
, pp. 42-50
-
-
Heider, U.1
Kaiser, M.2
Sterz, J.3
-
61
-
-
34248362003
-
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak
-
Perez-Galan P, Roue G, Villamor N, et al.: The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007, 109:4441-4449.
-
(2007)
Blood
, vol.109
, pp. 4441-4449
-
-
Perez-Galan, P.1
Roue, G.2
Villamor, N.3
-
62
-
-
0038473927
-
Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group
-
Kouroukis CT, Belch A, Crump M, et al.: Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:1740-1745.
-
(2003)
J Clin Oncol
, vol.21
, pp. 1740-1745
-
-
Kouroukis, C.T.1
Belch, A.2
Crump, M.3
-
63
-
-
33846219417
-
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
-
Byrd JC, Lin TS, Dalton JT, et al.: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109:399-404.
-
(2007)
Blood
, vol.109
, pp. 399-404
-
-
Byrd, J.C.1
Lin, T.S.2
Dalton, J.T.3
-
64
-
-
33747890672
-
Flavopiridol, fludarabine and rituximab is a highly active regimen in indolent B-cell lymphoproliferative disorders including mantle cell lymphoma
-
Lin TS, Fischer B, Moran M, et al.: Flavopiridol, fludarabine and rituximab is a highly active regimen in indolent B-cell lymphoproliferative disorders including mantle cell lymphoma. Blood 2005, 106:944.
-
(2005)
Blood
, vol.106
, pp. 944
-
-
Lin, T.S.1
Fischer, B.2
Moran, M.3
-
65
-
-
34249075706
-
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
-
Robertson MJ, Kahl BS, Vose JM, et al.: Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007, 25:1741-1746.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1741-1746
-
-
Robertson, M.J.1
Kahl, B.S.2
Vose, J.M.3
-
66
-
-
0038206722
-
Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis
-
Pham LV, Tamayo AT, Yoshimura LC, et al.: Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003, 171:88-95.
-
(2003)
J Immunol
, vol.171
, pp. 88-95
-
-
Pham, L.V.1
Tamayo, A.T.2
Yoshimura, L.C.3
-
67
-
-
0141953292
-
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resisance in lymphoma cells
-
Chauhan D, Li G, Shringarpure R, et al.: Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resisance in lymphoma cells. Cancer Res 2003, 63:6174-6177.
-
(2003)
Cancer Res
, vol.63
, pp. 6174-6177
-
-
Chauhan, D.1
Li, G.2
Shringarpure, R.3
|